Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is reportedly the fifth most common malignancy in the world. Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) was approved in 2020 as the first immune-combined therapy and the standard of care for first-line systemic treatment of unresec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinami, Takahiro, Amioka, Kei, Kawaoka, Tomokazu, Uchikawa, Shinsuke, Yamasaki, Shintaro, Kosaka, Masanari, Johira, Yusuke, Yano, Shigeki, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Fujii, Yasutoshi, Fujino, Hatsue, Nakahara, Takashi, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Miki, Daiki, Tsuge, Masataka, Imamura, Michio, Aikata, Hiroshi, Oka, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137288/
https://www.ncbi.nlm.nih.gov/pubmed/37190231
http://dx.doi.org/10.3390/cancers15082304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137288/
https://www.ncbi.nlm.nih.gov/pubmed/37190231
http://dx.doi.org/10.3390/cancers15082304

Ejemplares similares